Venatorx Pharmaceuticals Expands Senior Leadership Team
Key Hires in CMC/Technical Operations, Business Development, and Finance
Venatorx Pharmaceuticals Expands Senior Leadership Team
Key Hires in CMC/Technical Operations, Business Development, and Finance
iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease
IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024
Vittoria Therapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam
No Clinical Safety or Efficacy Issues Identified
No Requirement for Further Clinical Data or Trials
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection
Cefepime-Taniborbactam Superior to Meropenem for the Composite Efficacy Endpoint
Composite Efficacy Sustained at Late Follow-up Visit
Safety Profile Consistent with Meropenem
Unite Us and Ride Health Partner to Improve Access to Transportation Services for New Yorkers
The Collaborative Initiative with Social Care Networks Will Overcome Obstacles to Vital Services Following New York State’s Approval of the 1115 Medicaid Waiver
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile
“Sean Lyden MD, Professor and Chairman Vascular Surgery Cleveland Clinic on the mainstage at ISET 2024”
SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.